X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3135) 3135
Publication (613) 613
Book Review (30) 30
Book Chapter (8) 8
Conference Proceeding (5) 5
Dissertation (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2256) 2256
index medicus (2065) 2065
animals (1584) 1584
janus kinase 2 - antagonists & inhibitors (970) 970
mice (959) 959
signal transduction (763) 763
janus kinase 2 - metabolism (743) 743
phosphorylation (687) 687
signal transduction - drug effects (686) 686
male (672) 672
janus kinase 2 (660) 660
female (628) 628
oncology (587) 587
protein kinase inhibitors - pharmacology (521) 521
janus kinase 2 - genetics (502) 502
activation (491) 491
hematology (479) 479
janus kinases - antagonists & inhibitors (477) 477
stat3 transcription factor - metabolism (477) 477
cell line, tumor (459) 459
cell biology (448) 448
mutation (424) 424
apoptosis (419) 419
expression (396) 396
biochemistry & molecular biology (391) 391
cells, cultured (385) 385
protein-tyrosine kinases - metabolism (366) 366
protein kinase inhibitors - therapeutic use (361) 361
kinases (351) 351
cell line (340) 340
cytokines (339) 339
rats (337) 337
immunology (336) 336
research (334) 334
enzyme inhibitors - pharmacology (324) 324
janus kinase (324) 324
janus kinases - metabolism (319) 319
article (312) 312
protein-tyrosine kinases - antagonists & inhibitors (308) 308
proteins (304) 304
polycythemia-vera (303) 303
phosphorylation - drug effects (301) 301
apoptosis - drug effects (298) 298
pharmacology & pharmacy (298) 298
jak2 (289) 289
tyrphostins - pharmacology (282) 282
cancer (280) 280
middle aged (279) 279
inflammation (263) 263
stat3 (261) 261
gene expression (259) 259
janus kinase 1 - antagonists & inhibitors (256) 256
myelofibrosis (254) 254
proto-oncogene proteins (246) 246
cell proliferation - drug effects (242) 242
stat3 transcription factor - antagonists & inhibitors (238) 238
adult (219) 219
abridged index medicus (218) 218
cells (218) 218
analysis (217) 217
pyrazoles - therapeutic use (214) 214
research article (212) 212
inhibition (208) 208
aged (207) 207
primary myelofibrosis - drug therapy (207) 207
care and treatment (206) 206
hemic and lymphatic diseases (206) 206
myeloproliferative neoplasms (205) 205
pyrimidines - pharmacology (205) 205
signal transduction - physiology (205) 205
health aspects (203) 203
treatment outcome (203) 203
antineoplastic agents - pharmacology (199) 199
dose-response relationship, drug (198) 198
myeloproliferative disorders (197) 197
genetic aspects (194) 194
janus kinase 3 - antagonists & inhibitors (189) 189
dna-binding proteins - metabolism (188) 188
receptor (187) 187
physiological aspects (186) 186
essential thrombocythemia (183) 183
mice, inbred c57bl (183) 183
trans-activators - metabolism (183) 183
leukemia (180) 180
gene-expression (177) 177
medicine (174) 174
stat transcription factors - metabolism (174) 174
ruxolitinib (172) 172
pathway (170) 170
transcription (168) 168
hormones, hormone substitutes, and hormone antagonists (167) 167
stat5 transcription factor - metabolism (164) 164
tyrosine kinase jak2 (164) 164
rodents (162) 162
blotting, western (161) 161
pyrazoles - pharmacology (161) 161
janus kinase 1 - metabolism (155) 155
multidisciplinary sciences (154) 154
jak (153) 153
proliferation (153) 153
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3099) 3099
Japanese (10) 10
Chinese (9) 9
French (5) 5
German (4) 4
Russian (4) 4
Danish (3) 3
Spanish (2) 2
Croatian (1) 1
Czech (1) 1
Norwegian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 09/2012, Volume 489, Issue 7414, pp. 155 - 159
The identification of somatic activating mutations in JAK2 (refs 1-4) and in the thrombopoietin receptor gene (MPL)(5) in most patients with myeloproliferative... 
MYELOFIBROSIS | LUNG-CANCER | POLYCYTHEMIA-VERA | GEFITINIB | MYELOPROLIFERATIVE DISORDERS | TYROSINE KINASE | MULTIDISCIPLINARY SCIENCES | BCR-ABL | MUTATION | RESISTANCE | CHRONIC MYELOID-LEUKEMIA | Myeloproliferative Disorders - enzymology | Phosphorylation | Protein Biosynthesis | Humans | Protein Multimerization | STAT Transcription Factors - metabolism | TYK2 Kinase - metabolism | Janus Kinase 1 - deficiency | TYK2 Kinase - deficiency | Myeloproliferative Disorders - pathology | Janus Kinase 1 - biosynthesis | Gene Knockdown Techniques | Janus Kinase 2 - deficiency | Janus Kinase 1 - metabolism | Granulocytes - drug effects | RNA Interference | Janus Kinase 1 - genetics | Janus Kinase 2 - metabolism | Myeloproliferative Disorders - metabolism | Granulocytes - metabolism | Janus Kinase 2 - antagonists & inhibitors | Disease Models, Animal | Cell Line | Janus Kinase 2 - genetics | Myeloproliferative Disorders - drug therapy | Enzyme Activation - drug effects | TYK2 Kinase - biosynthesis | Granulocytes - enzymology | Animals | Signal Transduction - drug effects | HSP90 Heat-Shock Proteins - antagonists & inhibitors | HSP90 Heat-Shock Proteins - metabolism | Mice | TYK2 Kinase - genetics | Drug Resistance, Neoplasm - drug effects | Enzyme inhibitors | Gene mutations | Cancer cells | Dosage and administration | Genetic aspects | Cellular signal transduction | Identification and classification | Physiological aspects | Care and treatment | Research | Myeloproliferative disorders | Cancer | tyrosine kinase inhibitors | persistence | MPN | JAK2 | resistance
Journal Article
Blood, ISSN 0006-4971, 04/2010, Volume 115, Issue 15, pp. 3109 - 3117
Journal Article
Blood, ISSN 0006-4971, 10/2012, Volume 120, Issue 17, pp. 3510 - 3518
CRLF2 rearrangements, JAK1/2 point mutations, and JAK2 fusion genes have been identified in Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia... 
MAMMALIAN TARGET | RAPAMYCIN | IN-VITRO | ABERRANT STAT5 | RECEPTOR | OF-FUNCTION MUTATIONS | HEMATOLOGY | B-PROGENITOR | GENETIC ALTERATIONS | STAT5 ACTIVATION | CRLF2 | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - metabolism | TOR Serine-Threonine Kinases - metabolism | Humans | Immunoglobulins - genetics | Molecular Targeted Therapy | Immunoglobulins - metabolism | TOR Serine-Threonine Kinases - antagonists & inhibitors | Janus Kinase 1 - metabolism | STAT5 Transcription Factor - genetics | STAT5 Transcription Factor - metabolism | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | TOR Serine-Threonine Kinases - genetics | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Janus Kinase 1 - genetics | Janus Kinase 2 - metabolism | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Receptors, Cytokine - metabolism | Drug Evaluation, Preclinical | Child | Philadelphia Chromosome | Receptors, Cytokine - genetics | Janus Kinase 2 - antagonists & inhibitors | Disease Models, Animal | Pyrazoles - pharmacology | Acute Disease | Janus Kinase 2 - genetics | Survival Rate | Signal Transduction - genetics | Janus Kinase 1 - antagonists & inhibitors | Sirolimus - pharmacology | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - genetics | Xenograft Model Antitumor Assays | Animals | Signal Transduction - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Lymphoid Neoplasia
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2012, Volume 366, Issue 9, pp. 799 - 807
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2010, Volume 363, Issue 12, pp. 1117 - 1127
Journal Article
The EMBO Journal, ISSN 0261-4189, 08/2012, Volume 31, Issue 17, pp. 3513 - 3523
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2012, Volume 366, Issue 9, pp. 787 - 798
Journal Article
11.